Credit: Thinkstock. KPI-012 is a topically dosed ophthalmic therapy designed using the Company's human mesenchymal stem cell secretome platform. The Food and Drug Administration (FDA) has granted Fast ...
Kala Bio missed the primary endpoint in the study for its treatment of Persistent Corneal Epithelial Defect, an eye defect, and said it would stop development of the drug, called KPI-012. The company ...
Recently reported findings indicate that cenegermin-bkbj ophthalmic solution (Oxervate; Dompé) may perform as an effective and generally well-tolerated option for patients in China with moderate or ...
-- KPI-012 is a novel secretome with a multifactorial mechanism of action for development in PCED and other orphan ocular surface diseases driven by impaired corneal healing ---- KPI-012 demonstrated ...
-- On-track to initiate Phase 2b trial in 1Q 2023; Topline data expected in 1Q 2024 -- -- Received remaining $25 million investment under previously announced private placement financing -- ARLINGTON, ...
-- On-track to initiate Phase 2b trial in 4Q 2022, with topline data expected in 1Q 2024 -- -- Cash runway extended into 1Q 2025, pending receipt of second tranche from previously announced financing, ...
Corneal defects often heal themselves, but serious injuries that are left untreated can result in inflammation, infection, ulceration and even blindness. A new study provides exciting evidence ...
Please provide your email address to receive an email when new articles are posted on . All eyes that received a single-layer graft and a 24-hour pressure patch showed complete healing. A three-layer ...
A corneal abrasion is an eye injury caused by a scratch or scrape on the cornea’s surface. A person’s fingernails, contact lenses, or other foreign objects can all cause a corneal abrasion. The cornea ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback